The proteasome inhibitor PS-341 in cancer therapy.

The anticancer activity of the boronic acid dipeptide proteasome inhibitor PS-341 was examined in vitro and in vivo. PS-341 was a potent cytotoxic agent toward MCF-7 human breast carcinoma cells in culture, producing an IC90 of 0.05 microM on 24 h of exposure to the drug. In the EMT-6 tumor cell survival assay, PS-341 was equally cytotoxic administered p.o. or by i.p. injection up to a dose of 2 mg/kg. PS-341 was also toxic to the bone marrow colony-forming unit-granulocyte macrophage. PS-341 increased the tumor cell killing of radiation therapy, cyclophosphamide, and cisplatin in the EMT-6/Parent tumor, but was not able to overcome the in vivo resistance of the EMT-6/CTX and EMT-6/CDDP tumors. In the tumor growth delay assay, PS-341 administered p.o. had antitumor activity against the Lewis lung carcinoma, both primary and metastatic disease. In combination, regimens with 5-fluorouracil, cisplatin, Taxol and adriamycin, PS-341 seemed to produce primarily additive tumor growth delays against the s.c. tumor and was highly effective against disease metastatic to the lungs. The proteasome is an interesting new target for cancer therapy, and the proteasome inhibitor PS-341 warrants continued investigation in cancer therapy.

[1]  M. Grever,et al.  Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.

[2]  S. Ōmura,et al.  Total Synthesis of (+)-Lactacystin , 1996 .

[3]  M. Ames,et al.  Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. , 1992, Invasion & metastasis.

[4]  Tom Maniatis,et al.  Regulation of Interferon-γ-Activated STAT1 by the Ubiquitin-Proteasome Pathway , 1996, Science.

[5]  B. Teicher,et al.  Transforming growth factor-β in in vivo resistance , 1996, Cancer Chemotherapy and Pharmacology.

[6]  L. Ignarro,et al.  Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Rousset,et al.  Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome , 1996, Nature.

[8]  T. Maniatis,et al.  Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. , 1996, Science.

[9]  D. Wolf,et al.  Proteasome and cell cycle , 1993, FEBS letters.

[10]  R F Standaert,et al.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.

[11]  S. Schreiber,et al.  A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Ōmura,et al.  Degradation Process of Ligand-stimulated Platelet-derived Growth Factor β -Receptor Involves Ubiquitin-Proteasome Proteolytic Pathway * , 1995, The Journal of Biological Chemistry.

[13]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[14]  B. Teicher,et al.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.

[15]  Wovkulich Peter Michael,et al.  Total synthesis of 1233A , 1993 .

[16]  D. Wolf,et al.  Proteasomes: destruction as a programme. , 1996, Trends in biochemical sciences.

[17]  S. Chatterjee,et al.  Potent inhibitors of proteasome. , 1995, Journal of medicinal chemistry.

[18]  Charles A. Kennedy,et al.  Immunosuppresive boronic acid dipeptides: correlation between conformation and activity , 1993 .

[19]  S. Ōmura,et al.  Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid. , 1995, Biochemical and biophysical research communications.

[20]  S. Ōmura,et al.  Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol-linked protein in a pre-Golgi compartment. , 1996, Biochemical and biophysical research communications.

[21]  R. Stein,et al.  Boronic ester and acid compounds, their synthesis and uses , 1995 .

[22]  A B Shenvi,et al.  alpha-Aminoboronic acid derivatives: effective inhibitors of aminopeptidases. , 1986, Biochemistry.

[23]  S. Ōmura,et al.  Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. , 1995, Biochemical and biophysical research communications.

[24]  Tom Maniatis,et al.  The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.

[25]  N. Soskel,et al.  A new peptide boronic acid inhibitor of elastase-induced lung injury in hamsters. , 1986, The American review of respiratory disease.

[26]  U. Lopes,et al.  p53-dependent Induction of Apoptosis by Proteasome Inhibitors* , 1997, The Journal of Biological Chemistry.

[27]  Charles A. Kennedy,et al.  Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond , 1994 .

[28]  B. Teicher,et al.  Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.

[29]  S. Ōmura,et al.  Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. , 1996, Cancer research.

[30]  A. Goldberg,et al.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.

[31]  B. Teicher,et al.  Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents , 1994, International journal of cancer.

[32]  J. Riordan,et al.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.

[33]  B. Teicher,et al.  Transforming growth factor-beta in in vivo resistance. , 1996, Cancer chemotherapy and pharmacology.

[34]  P. Howley,et al.  In vivo ubiquitination and proteasome-mediated degradation of p53(1). , 1996, Cancer research.

[35]  J. Adams,et al.  CHAPTER 28. NOVEL INHIBITORS OF THE PROTEASOME AND THEIR THERAPEUTIC USE IN INFLAMMATION , 1996 .

[36]  A. Goldberg,et al.  The molecular chaperone Ydj1 is required for the p34CDC28-dependent phosphorylation of the cyclin Cln3 that signals its degradation , 1996, Molecular and cellular biology.

[37]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[38]  R. Knabb,et al.  The selective inhibition of thrombin by peptides of boroarginine. , 1990, The Journal of biological chemistry.

[39]  B. Teicher,et al.  Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. , 1987, Cancer research.

[40]  M. Kirschner,et al.  Ubiquitination of the G1 cyclin Cln2p by a Cdc34p‐dependent pathway. , 1995, The EMBO journal.

[41]  Bruce Futcher,et al.  Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins , 1995, Nature.